<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756833</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00051170</org_study_id>
    <secondary_id>R01AG037120</secondary_id>
    <nct_id>NCT01756833</nct_id>
  </id_info>
  <brief_title>Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial</brief_title>
  <acronym>N-TA^3CT</acronym>
  <official_title>Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA^3CT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this study is to determine if doxycycline (100 mg bid) will inhibit (by at&#xD;
      least 40%) the increase in greatest transverse diameter of small abdominal aortic aneurysms&#xD;
      (3.5-5.0 cm in men, 3.5-4.5 cm in women) over a 24-month period of observation in comparison&#xD;
      to a placebo-treated control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      N-TA^3CT is a randomized, double-blind, placebo-controlled test of the hypothesis that&#xD;
      doxycycline 100 mg bid, will reduce the rate of increase of maximum transverse diameter of&#xD;
      small (3.5-5.0 cm among men and 3.5 to 4.5 cm among women) abdominal aortic aneurysms. The&#xD;
      primary outcome is abdominal aortic aneurysm (AAA) maximum transverse diameter determined by&#xD;
      CT scans at two-year follow-up with allowance for baseline (pre-randomization) diameter.&#xD;
      Based on an anticipated growth rate of 2.5 mm per year in the placebo group and the current&#xD;
      threshold at which surgical intervention will be offered to trial participants, (5.5 cm in&#xD;
      men, 5.0 cm in women), the upper limit of AAA size for inclusion has been set at 5.0 cm for&#xD;
      men and 4.5 cm for women. Among these subjects, the threshold for repair would be exceeded&#xD;
      only by those exhibiting persistent growth. Secondary outcomes will determine if doxycycline&#xD;
      affects other measures, e.g., MMP-9 levels in plasma and whether these effects are related to&#xD;
      aneurysm growth. Nineteen clinical sites have identified pools of over 1600 patients with&#xD;
      small aneurysm who meet the proposed inclusion/exclusion criteria. Two hundred fifty-eight&#xD;
      patients will be randomized to placebo or doxycycline and their aneurysms followed for change&#xD;
      in diameter at six-month intervals using CT imaging. The alternative hypothesis is that&#xD;
      doxycycline will inhibit the expansion rate by 40% during the two years of observation.&#xD;
      Patients enrolling in N-TA^3CT must be able to give consent for their participation&#xD;
      themselves and meet study eligibility criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Actual">July 23, 2019</completion_date>
  <primary_completion_date type="Actual">July 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome is growth in abdominal aortic aneurysm (AAA) maximum transverse diameter determined by CT scans at two-year follow-up with allowance for baseline (pre-randomization) diameter.</measure>
    <time_frame>Two and one-half to three years</time_frame>
    <description>Based on an anticipated growth rate of 2.5 mm per year in the placebo group and the current threshold at which surgical intervention will be offered to trial participants, (5.5 cm in men, 5.0 cm in women), the upper limit of AAA size for inclusion has been set at 5.0 cm for men and 4.5 cm for women. Among these subjects, the threshold for surgical repair would be exceeded only by those exhibiting persistent growth.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes will determine if doxycycline affects other measures, e.g., MMP-9 levels in plasma, and whether these effects are related to aneurysm growth.</measure>
    <time_frame>Two and one-half to three years</time_frame>
    <description>Secondary outcomes will derive from central, Imaging Core Laboratory analyses of the CT scans performed every six months on patients and from the clinical follow-up of randomized patients, from clinical observation, local laboratory findings, study visit quality of life assessments, and from biomarker analyses to be performed in the Biomarkers Core Laboratory (e.g., changes from initial matrix metalloproteinase (MMP-9) levels, and matrix metalloproteinase (MMP-9) levels at 24 months of follow-up).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes will determine if doxycycline affects other measures, e.g., Interferon-gamma levels, and whether these effects are related to aneurysm growth.</measure>
    <time_frame>Two and one-half to three years</time_frame>
    <description>Secondary outcomes will derive from central, Imaging Core Laboratory analyses of the CT scans performed every six months on patients and from the clinical follow-up of randomized patients, from clinical observation, local laboratory findings, study visit quality of life assessments, and from biomarker analyses to be performed in the Biomarkers Core Laboratory (e.g., changes from initial Interferon-gamma levels, and Interferon-gamma levels at 24 months of follow-up).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Aneurysm volume and other characteristics</measure>
    <time_frame>Two and one-half to three years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Aneurysm rupture</measure>
    <time_frame>Two and one-half to three years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Surgical intervention</measure>
    <time_frame>Two and one-half to three years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Death</measure>
    <time_frame>Two and one-half to three years</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">261</enrollment>
  <condition>Aneurysm</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg capsules, twice a day, for a period of two years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 mg capsules, twice a day, for a period of two years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>100 mg po bid</description>
    <arm_group_label>Doxycycline</arm_group_label>
    <other_name>doxycycline hyclate</other_name>
    <other_name>Vibramycin</other_name>
    <other_name>Oracea</other_name>
    <other_name>Adoxa</other_name>
    <other_name>Atridox and others</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>capsule identical to the doxycycline capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>capsule containing inert filler</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 55 years of age or older, women post-surgical menopause or at least two years&#xD;
             since last menses if natural menopause.&#xD;
&#xD;
          -  CT scan documented infrarenal abdominal aortic aneurysm with maximum transverse&#xD;
             diameter larger than 35 mm and no greater than 50 mm, in men, and larger than 35 mm&#xD;
             and no greater than 45 mm in women.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded from the study if they are unable to give their own informed&#xD;
             consent to participate.&#xD;
&#xD;
          -  have symptoms related to abdominal aortic aneurysm.&#xD;
&#xD;
          -  have other intra-abdominal vascular pathology that may require repair within 24 months&#xD;
             (e.g., renal artery stenosis, large iliac artery aneurysms, iliac occlusive disease,&#xD;
             aneurysmal involvement of the renal artery).&#xD;
&#xD;
          -  have had previous abdominal aortic aneurysm repair by open surgical or endovascular&#xD;
             technique.&#xD;
&#xD;
          -  have an active malignancy with life expectancy less than two years.&#xD;
&#xD;
          -  have an allergy to tetracycline.&#xD;
&#xD;
          -  are currently or have been recently treated (previous six months) with tetracycline&#xD;
             derivatives.&#xD;
&#xD;
          -  they are currently taking anti-seizure medicines metabolized by pathways influenced by&#xD;
             doxycycline (e.g., carbamazepine, phenytoin, and barbiturates).&#xD;
&#xD;
          -  stage II hypertension (patients whose blood pressure is persistently in the range of&#xD;
             systolic &gt; 160 mm Hg or diastolic &gt; 100 mm Hg despite primary physician's best effort&#xD;
             to achieve adequate therapy.&#xD;
&#xD;
          -  have dialysis dependent renal failure or impending dialysis treatment for renal&#xD;
             insufficiency.&#xD;
&#xD;
          -  have a chronic infection requiring long-term (&gt; 2 weeks) antibiotics.&#xD;
&#xD;
          -  have known genetic syndromes responsible for the abdominal aortic aneurysm (e.g.,&#xD;
             Marfan's Syndrome).&#xD;
&#xD;
          -  are under treatment with systemic immunosuppressive agents.&#xD;
&#xD;
          -  could become pregnant.&#xD;
&#xD;
          -  are not good candidates for clinical trial participation.&#xD;
&#xD;
          -  are enrolled in another clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael L Terrin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard T Baxter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan Matsumura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Curci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carondelet Heart &amp; Vascular Institute</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Cardiac and Vascular Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida Health Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconness Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McLaren Northern Michigan</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omaha VAMC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Portland VAMC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah VAMC</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baxter BT, Matsumura J, Curci J, McBride R, Blackwelder WC, Liu X, Larson L, Terrin ML; N-TA(3)CT Investigators. Non-invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA(3)CT): Design of a Phase IIb, placebo-controlled, double-blind, randomized clinical trial of doxycycline for the reduction of growth of small abdominal aortic aneurysm. Contemp Clin Trials. 2016 May;48:91-8. doi: 10.1016/j.cct.2016.03.008. Epub 2016 Mar 25.</citation>
    <PMID>27018941</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>December 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2012</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Michael Terrin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>abdominal</keyword>
  <keyword>aortic</keyword>
  <keyword>aneurysm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 31, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT01756833/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT01756833/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 2, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT01756833/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <pending_results>
    <submitted>May 7, 2021</submitted>
    <returned>June 2, 2021</returned>
    <submitted>July 27, 2021</submitted>
    <returned>August 20, 2021</returned>
    <submitted>September 10, 2021</submitted>
    <returned>October 7, 2021</returned>
    <submitted>October 29, 2021</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

